H. Lundbeck A/S – Product Pipeline Review

Global Markets Direct’s, ‘H. Lundbeck A/S – Product Pipeline Review – 2016’, provides an overview of the H. Lundbeck A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by H. Lundbeck A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of H. Lundbeck A/S

The report provides overview of H. Lundbeck A/S including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses H. Lundbeck A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features H. Lundbeck A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate H. Lundbeck A/S’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for H. Lundbeck A/S

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding H. Lundbeck A/S’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

H. Lundbeck A/S Snapshot 6

H. Lundbeck A/S Overview 6

Key Information 6

Key Facts 6

H. Lundbeck A/S - Research and Development Overview 7

Key Therapeutic Areas 7

H. Lundbeck A/S - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

H. Lundbeck A/S - Pipeline Products Glance 15

H. Lundbeck A/S - Late Stage Pipeline Products 15

Filing rejected/Withdrawn Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

H. Lundbeck A/S - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

H. Lundbeck A/S - Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

H. Lundbeck A/S - Drug Profiles 21

carbamazepine 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

idalopirdine 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

LuAF-35700 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

nalmefene 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

vortioxetine hydrobromide 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

LuAF-11167 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

LUAF-20513 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

LUAF-64280 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

AF-40431 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Brain Diseases 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecules to Inhibit LRRK-2 for Parkinson's Disease 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

H. Lundbeck A/S - Pipeline Analysis 36

H. Lundbeck A/S - Pipeline Products by Target 36

H. Lundbeck A/S - Pipeline Products by Route of Administration 38

H. Lundbeck A/S - Pipeline Products by Molecule Type 39

H. Lundbeck A/S - Pipeline Products by Mechanism of Action 40

H. Lundbeck A/S - Recent Pipeline Updates 42

H. Lundbeck A/S - Dormant Projects 48

H. Lundbeck A/S - Discontinued Pipeline Products 49

Discontinued Pipeline Product Profiles 49

gaboxadol 49

LuAA-47070 49

idalopirdine 49

Lu-02750 50

Lu-35138 50

Lu-AA24493 50

LuAA-37096 50

LuAA-38466 50

LuAA-39959 50

LuAA-44608 51

LuAE-04621 51

ORE-10002 51

siramesine 51

tedatioxetine hydrobromide 51

vortioxetine hydrobromide 51

zicronapine 52

H. Lundbeck A/S - Company Statement 53

H. Lundbeck A/S - Locations And Subsidiaries 54

Head Office 54

Other Locations & Subsidiaries 54

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

List of Tables

H. Lundbeck A/S, Key Information 6

H. Lundbeck A/S, Key Facts 6

H. Lundbeck A/S – Pipeline by Indication, 2016 8

H. Lundbeck A/S – Pipeline by Stage of Development, 2016 9

H. Lundbeck A/S – Monotherapy Products in Pipeline, 2016 10

H. Lundbeck A/S – Partnered Products in Pipeline, 2016 11

H. Lundbeck A/S – Partnered Products/ Combination Treatment Modalities, 2016 12

H. Lundbeck A/S – Out-Licensed Products in Pipeline, 2016 13

H. Lundbeck A/S – Out-Licensed Products/ Combination Treatment Modalities, 2016 14

H. Lundbeck A/S – Filing rejected/Withdrawn, 2016 15

H. Lundbeck A/S – Phase III, 2016 16

H. Lundbeck A/S – Phase II, 2016 17

H. Lundbeck A/S – Phase I, 2016 18

H. Lundbeck A/S – Preclinical, 2016 19

H. Lundbeck A/S – Discovery, 2016 20

H. Lundbeck A/S – Pipeline by Target, 2016 36

H. Lundbeck A/S – Pipeline by Route of Administration, 2016 38

H. Lundbeck A/S – Pipeline by Molecule Type, 2016 39

H. Lundbeck A/S – Pipeline Products by Mechanism of Action, 2016 40

H. Lundbeck A/S – Recent Pipeline Updates, 2016 42

H. Lundbeck A/S – Dormant Developmental Projects,2016 48

H. Lundbeck A/S – Discontinued Pipeline Products, 2016 49

H. Lundbeck A/S, Subsidiaries 54

List of Figures

List of Figures

H. Lundbeck A/S – Pipeline by Top 10 Indication, 2016 8

H. Lundbeck A/S – Pipeline by Stage of Development, 2016 9

H. Lundbeck A/S – Monotherapy Products in Pipeline, 2016 10

H. Lundbeck A/S – Partnered Products in Pipeline, 2016 11

H. Lundbeck A/S – Out-Licensed Products in Pipeline, 2016 13

H. Lundbeck A/S – Pipeline by Top 10 Target, 2016 36

H. Lundbeck A/S – Pipeline by Route of Administration, 2016 38

H. Lundbeck A/S – Pipeline by Molecule Type, 2016 39

H. Lundbeck A/S – Pipeline Products by Top 10 Mechanism of Action, 2016 40

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports